Lv4
514 积分 2024-05-25 加入
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
25天前
已完结
Trispecific engager overcomes tumoural immunosuppressive environment
1个月前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
1个月前
已完结
Nanobodies: a new paradigm for brain disorder therapies
1个月前
已完结
Masking T cell engagers mitigates on-target off-tumor activity
1个月前
已完结
Past, present and future of drug conjugates for cancer therapy
1个月前
已完结
Fine tuning towards the next generation of engineered T cells
1个月前
已完结
RNA chemistry and therapeutics
3个月前
已完结
AI-driven protein design
3个月前
已完结
Balancing weight and muscle loss in GLP1 receptor agonist therapy
4个月前
已完结
皖公网安备34019202002308
